NRX Pharmaceuticals, Inc. - Common Stock NRXP 深 沪
等待开盘 10-03 09:30:00 美东时间
3.33
-0.010
-0.30%
华盛通- 最 高3.40
- 今 开3.38
- 成交量 26.02万股
- 最 低 3.20
- 昨 收 3.34
- 总市值 7915.38万
- 52周最高 6.01
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.10
- 委 比 -45.01%
- 总股本 2376.99万
- 历史最高 769.90
- 量 比 0.64
- 振 幅 5.99%
- 历史最低 1.58
- 每 手 1
- 风险率 0.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅162.68%！Ocular Therapeutix获JMP证券升目标价至29美元，维持"跑赢大市"评级
今日重点评级关注：JMP证券：维持Ocular Therapeutix"跑赢大市"评级，目标价从20美元升至29美元；汇丰银行：上调Banco BBVA Argentina评级至"买入"，目标价从21美元下调至17美元
10-02 15:08
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine
NRx Pharmaceuticals has refiled its ANDA for KETAFREE™, a preservative-free IV ketamine formulation, following FDA approval of its Suitability Petition. The product aims to address the current US ketamine shortage and aligns with HHS priorities to eliminate toxic preservatives. The global ketamine market is valued at $750 million and projected to reach $3.35 billion by 2034. NRx’s preservative-free formula eliminates benzethonium chloride, a neur...
09-29 12:03
NRx Pharmaceuticals Announces FDA Has Granted Suitability Petition For Its Planned Preservative-Free Ketamine Product Ketafree
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, announced that it was notified yesterday by the United States Food and Drug Administration that a Suitability Petition has been granted
09-24 20:07
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine
NRx Pharmaceuticals received FDA approval for its Suitability Petition, enabling it to re-file the Abbreviated New Drug Application (ANDA) for its preservative-free, single-patient dose ketamine product, KETAFREE™. The product addresses the administration's goals of re-shoring critical drugs and removing toxic preservatives. Currently, ketamine is sold with Benzethonium Chloride, a toxic preservative. The Company plans to bring KETAFREE™ to the U...
09-24 12:03
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Nurix Therapeutics and Gilead Sciences have advanced GS-6791, a novel IRAK4 degrader, into clinical testing for inflammatory diseases. Preclinical data, presented at the EADV Congress, demonstrate GS-6791's ability to degrade IRAK4, inhibiting IL-1 and IL-36 responses and reducing disease in a model of atopic dermatitis. Serving as a potent, selective, and oral therapy, GS-6791 has shown promise in treating inflammatory conditions. The ongoing Ph...
09-17 11:00
NRX Pharmaceuticals Completes Acquisition of Dura Medical
NRX Pharmaceuticals ( ($NRXP) ) has issued an update. On September 8, 2025, NRx...
09-13 05:04
NRX Pharmaceuticals Raises $8.8 Million in Stock Offering
An announcement from NRX Pharmaceuticals ( ($NRXP) ) is now available. On Septe...
09-09 05:06
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $34 price target.
09-08 22:09
NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th
NRx Pharmaceuticals' CEO Jonathan Javitt will participate in a fireside chat at H.C. Wainwright’s Global Investment Conference on Sept. 8, 2025. The event will be webcast and available for replay. NRx, focused on NMDA-targeted therapeutics for CNS disorders like suicidal depression, has filed applications for its ketamine-based treatments. Its subsidiary, HOPE Therapeutics, plans to build interventional psychiatry clinics offering ketamine and ot...
09-03 12:03
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital
NRx Pharmaceuticals announced plans to launch HOPE Therapeutics clinics in September 2025, starting with a flagship location in Palm Beach, Florida. The company recently raised $8.8 million from biotech investors. HOPE clinics will combine neuroplastic drugs like ketamine, transcranial magnetic stimulation, and hyperbaric oxygen therapy to treat suicidal depression, PTSD, and cognitive dysfunction. Matthew Rockefeller joined the HOPE Therapeutics...
09-02 12:41
